Source: International Congress 2017 – Clinical points to ponder in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gomez-Bastero (Sevilla, Spain). Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study. 636

Member's Comments

No comment yet.

Related content which might interest you: Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Clinical characteristics and burden of illness in a cohort of severe asthma patients Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016 Short-term evaluation of a remote patient support program in patients with COPD and frequent exacerbations. ESOPO study Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 Cost of asthma in patients treated with national asthma guideline in Turkey Source: Eur Respir J 2003; 22: Suppl. 45, 481s Year: 2003 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Health care costs in COPD patients with severe respiratory failure: a prospective analysis Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Incidence and severity of acute exacerbations among women enrolled in an asthma management program during pregnancy: A prospective study of 1.283 pregnancies Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Effectiveness of montelukast on asthma control in infants: A claims data study Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Effectiveness of self-treatment of exacerbations in COPD patients: Two-year follow-up of the COPE-II study Source: International Congress 2014 – Best abstracts in rehabilitation and chronic care (sponsored by MOTEK Medical) Year: 2014 The impact of the addition of omalizumab on the utilization of healthcare resources by severe persistent asthma patients Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Risk factors for self-reported hospitalizations among stable outpatients with COPD Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes Source: International Congress 2016 – Airway stenting and ablation Year: 2016 Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot study Source: International Congress 2014 – The assessment of comorbidities Year: 2014